Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All fluvoxamine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFluvoxamineFluvoxamine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ PASC, SSRI 10% Improvement Relative Risk PASC, fluoxetine 15% SSRI for COVID-19  Butzin-Dozier et al.  Prophylaxis Is prophylaxis with SSRI beneficial for COVID-19? Retrospective study in the USA (September 2021 - December 2022) Lower PASC with SSRI (p=0.000009) c19early.org Butzin-Dozier et al., medRxiv, February 2024 Favors SSRI Favors control

SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression

Butzin-Dozier et al., medRxiv, doi:10.1101/2024.02.05.24302352
Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
27th treatment shown to reduce risk in November 2021
 
*, now known with p = 0.00011 from 20 studies, recognized in 3 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19early.org
N3C retrospective 506,903 outpatients with depression showing lower risk of long COVID with SSRI use. There was insufficient sample size to analyze the subgroup of fluvoxamine users.
risk of PASC, 9.9% lower, OR 0.90, p < 0.001, adjusted per study, SSRI, multivariable, RR approximated with OR.
risk of PASC, 15.3% lower, OR 0.85, p = 0.002, adjusted per study, fluoxetine, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Butzin-Dozier et al., 6 Feb 2024, retrospective, USA, preprint, 11 authors, study period 1 September, 2021 - 1 December, 2022.
This PaperFluvoxamineAll
SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression
PhD, MPH Zachary Butzin-Dozier, Yunwen Ji, Sarang Deshpande, Eric Hurwitz, Jeremy Coyle, Junming (seraphina) Shi, Andrew Mertens, Mark J Van Der Laan, John M Colford Jr, Rena C Patel, Alan E Hubbard
doi:10.1101/2024.02.05.24302352
Background: Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is a poorly understood condition with symptoms across a range of biological domains that often have debilitating consequences. Some have recently suggested that lingering SARS-CoV-2 virus in the gut may impede serotonin production and that low serotonin may drive many Long COVID symptoms across a range of biological systems. Therefore, selective serotonin reuptake inhibitors (SSRIs), which increase synaptic serotonin availability, may prevent or treat Long COVID. SSRIs are commonly prescribed for depression, therefore restricting a study sample to only include patients with depression can reduce the concern of confounding by indication. Methods: In an observational sample of electronic health records from patients in the National COVID Cohort Collaborative (N3C) with a COVID-19 diagnosis between September 1, 2021, and December 1, 2022, and pre-existing major depressive disorder, the leading indication for SSRI use, we evaluated the relationship between SSRI use at the time of COVID-19 infection and subsequent 12-month risk of Long COVID (defined by ICD-10 code U09.9). We defined SSRI use as a prescription for SSRI medication beginning at least 30 days before COVID-19 infection and not ending before COVID-19 infection. To minimize bias, we estimated the causal associations of interest using a nonparametric approach, targeted maximum likelihood estimation, to aggressively adjust for highdimensional covariates. Results: We analyzed a sample (n = 506,903) of patients with a diagnosis of major depressive disorder before COVID-19 diagnosis, where 124,928 (25%) were using an SSRI. We found that SSRI users had a significantly lower risk of Long COVID compared to nonusers (adjusted causal relative risk 0.90, 95% CI (0.86, 0.94)). Conclusion: These findings suggest that SSRI use during COVID-19 infection may be protective against Long COVID, supporting the hypothesis that serotonin may be a key mechanistic biomarker of Long COVID.
Disclaimer The N3C Publication committee confirmed that this manuscript (MSID:1784.118) is in accordance with N3C data use and attribution policies; however, this content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program. IRB The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources. This research project was approved by the University of California, Berkeley Committee for the Protection of Human Subjects (CPHS protocol number 2022-01-14980). This approval is issued under University of California, Berkeley Federalwide Assurance #00006252. Individual Acknowledgements For Core Contributors We gratefully acknowledge the following core contributors to N3C: Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin, Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks, Brijesh Patel, Caleb Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-Brown, Christine Suver, Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego..
References
Alkhamees, Obsessive-compulsive disorder post-COVID-19: a case presentation, Egypt J Neurol Psychiatr Neurosurg, doi:10.1186/s41983-021-00405-1
Beasley, Phenotype Data Acquisition
Belluck, Scientists Offer a New Explanation for Long Covid, The New York Times
Bramante, Buse, Liebovitz, Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(23)00299-2
Butzin-Dozier, Ji, Li, Predicting Long COVID in the National COVID Cohort Collaborative Using Super Learner, medRxiv. Published online, doi:10.1101/2023.07.27.23293272
Carone, Petersen, Laan, Targeted Minimum Loss-Based Estimation of a Causal Effect Using Interval-Censored Time-to-Event Data, doi:10.1201/b12290-11
Chu, Wadhwa, Selective Serotonin Reuptake Inhibitors
Coyle, Hejazi, Malenica, Targeted Learning, Wiley StatsRef: Statistics Reference Online, doi:10.1002/9781118445112.stat08414
Davis, Mccorkell, Vogel, Topol, Long COVID: major findings, mechanisms and recommendations, Nat Rev Microbiol, doi:10.1038/s41579-022-00846-2
Dunham, Venton, SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila, J Neurochem, doi:10.1111/jnc.15658
Foletto, Da Rosa, Serafin, Hörner, Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use, Eur J Clin Pharmacol, doi:10.1007/s00228-022-03372-5
Gruber, Lee, Phillips, Ho, Van Der Laan, Developing a Targeted Learning-Based Statistical Analysis Plan, Statistics in Biopharmaceutical Research, doi:10.1080/19466315.2022.2116104
Hashimoto, Overview of the potential use of fluvoxamine for COVID-19 and long COVID, Discov Ment Health, doi:10.1007/s44192-023-00036-3
Hernán, Clayton, Keiding, The Simpson's paradox unraveled, Int Epidemiol, doi:10.1093/ije/dyr041
Kamijima, Murasaki, Asai, Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients, Psychiatry Clin Neurosci, doi:10.1111/j.1440-1819.2004.01278.x
Marti, Pfaff, French, Farrukh, Koraishy et al., Details of contributions available at covid.cd2h.org/corecontributors
Mcgrath, Scott, Surinach, Chambers, Benigno et al., Use of the Postacute Sequelae of COVID-19 Diagnosis Code in Routine Clinical Practice in the US, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.35089
Montgomery, Kasper, Stein, Hedegaard, Lemming, Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessivecompulsive disorder, Int Clin Psychopharmacol, doi:10.1097/00004850-200103000-00002
Munoz, Der Laan, Sensitivity Analysis for Causal Inference Under Unmeasured Confounding and Measurement Error Problems
Pallanti, Quercioli, Koran, Citalopram intravenous infusion in resistant obsessivecompulsive disorder: an open trial, J Clin Psychiatry
Peace, Interval-Censored Time-to-Event Data: Methods and Applications, doi:10.1201/b12290
Pfaff, Girvin, Bennett, Identifying who has long COVID in the USA: a machine learning approach using N3C data, Lancet Digit Health, doi:10.1016/S2589-7500(22)00048-6
Pfaff, Girvin, Bennett, Identifying who has long COVID in the USA: a machine learning approach using N3C data, Lancet Digit Health, doi:10.1016/S2589-7500(22)00048-6
Pfaff, Madlock-Brown, Baratta, Coding long COVID: characterizing a new disease through an ICD-10 lens, BMC Med, doi:10.1186/s12916-023-02737-6
Phillips, Van Der Laan, Lee, Gruber, Practical considerations for specifying a super learner, International Journal of Epidemiology, doi:10.1093/ije/dyad023
Preskorn, Clinical Pharmacology of Serotonin Selective Reuptake Inhibitors
Raveendran, Jayadevan, Sashidharan, Long COVID: an overview, Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Reese, Blau, Casiraghi, Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes, eBioMedicine, doi:10.1016/j.ebiom.2022.104413
Reis, Santos Moreira-Silva, Silva, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health, doi:10.1016/S2214-109X(21)00448-4
Robertson, Qasmieh, Kulkarni, The Epidemiology of Long Coronavirus Disease in US Adults, Clin Infect Dis, doi:10.1093/cid/ciac961
Rus, De Vries, De Vries, Nutma, Kooij, Treatment of 95 post-Covid patients with SSRIs, Scientific Reports, doi:10.1038/s41598-023-45072-9
Schuler, Rose, Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies, Am J Epidemiol, doi:10.1093/aje/kww165
Sidky, Sahner, Girvin, Hotaling, Michael et al., Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19. medRxiv : the preprint server for health sciences, Published online, doi:10.1101/2022.11.09.22282142
Stingl, Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle, BJPsych Open, doi:10.1192/bjo.2021.1075
Van Der Laan, Coyle, Hejazi, Malenica, Phillips et al., Targeted Learning in R: Causal Data Science with the Tlverse Software Ecosystem
Van Der Laan, Polley, Hubbard, Super learner, Stat Appl Genet Mol Biol, doi:10.2202/1544-6115.1309
Van Der Laan, Rose, Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies
Van Der Laan, Rose, Targeted Learning: Causal Inference for Observational and Experimental Data
Van Der Laan, Why We Need a Statistical Revolution
Wong, Devason, Umana, Serotonin reduction in post-acute sequelae of viral infection, Cell, doi:10.1016/j.cell.2023.09.013
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit